Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced positive top-line results from a Phase III trial showing that its investigational drug candidate ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE